Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised

Arquivos de Neuro-Psiquiatria

Emmanuelle Sobreira¹  Márcio A. Pena-pereira¹  Alan L. Eckeli¹  Manoel A. Sobreira-neto¹  Marcos H. N. Chagas¹  Maria P. Foss¹  Brenna Cholerton¹  Cyrus P. Zabetian¹  Ignacio F. Mata¹  Vitor Tumas¹ 

关键词: MoCA;    ACE-R;    Parkinson's disease;    mild cognitive impairment;    dementia;    cognitive assessment;    neuropsychological tests;    MoCA;    ACE-R;    doença de Parkinson;    comprometimento cognitivo leve;    demência;    avaliação cognitiva;    testes neuropsicológicos;   

DOI  :  10.1590/0004-282X20150156

来源: SciELO

【 摘 要 】

ABSTRACTObjective The aim of the present study is to examine the accuracy of the Brazilian versions of the Montreal Cognitive Assessment (MoCA) and the Addenbrooke's Cognitive Examination-Revised (ACE-R) to screen for mild cognitive impairment (PDMCI) and dementia (PDD) in patients with Parkinson's disease (PD).Method Both scales were administered to a final convenience sample of 79 patients with PD. Patients were evaluated by a neurologist, a psychiatrist and a neuropsychologist using UPDRS, Hoehn and Yahr and Schwab and England scales, global deterioration scale, a psychiatric structured interview, Mattis Dementia Rating Scale and other cognitive tests.Results There were 32 patients with PDMCI and 17 patients with PDD. The MoCA and the ACE-R were able to discriminate patients with PDD from the others.Conclusion Both scales showed to be useful to screen for dementia but not for mild cognitive impairment in patients with PD.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License